As the US Food and Drug Administration’s patient-focused drug development initiative hits the 10-year mark, stakeholders are eyeing ways the program has evolved and additional changes they would like to see.
Primary responsibility for organizing and leading PFDD meetings in specific disease areas has shifted from the FDA to patient advocacy...






